Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1

被引：28

作者：

Bayle, A. ^{[1
]}

Khettab, M. ^{[2
]}

Lucibello, F. ^{[3
]}

Chamseddine, A. N. ^{[4
]}

Goldschmidt, V. ^{[5
]}

Perret, A. ^{[6
]}

Ropert, S. ^{[7
]}

Scotte, F. ^{[8
]}

Loulergue, P. ^{[9
]}

Mir, O. ^{[5
]}

机构：

[1] Gustave Roussy Canc Inst, Dept Drug Dev DITEP, Villejuif, France

[2] Gustave Roussy Canc Inst, Dept Canc Med, Chevilly Larue, France

[3] Paris Sci & Lettres Univ, Curie Inst, INSERM, U932, Paris, France

[4] Gustave Roussy Canc Inst, Dept Int Patients Canc Care, Villejuif, France

[5] Gustave Roussy Canc Inst, Ambulatory Canc Care, Villejuif, France

[6] Gustave Roussy Canc Inst, Canc Med, Villejuif, France

[7] Antony Private Hosp, Dept Med Oncol, Antony, France

[8] Foch Hosp, Dept Med Oncol, Suresnes, France

[9] Hotel Dieu Teaching Hosp, Dept Infect Dis, Paris, France

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷 / 07期

关键词：

DOCETAXEL;

D O I：

10.1016/j.annonc.2020.03.290

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：959 / 961

页数：3

共 50 条

[1] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
Iosune Baraibar
Ignacio Melero
Mariano Ponz-Sarvise
Eduardo Castanon
Drug Safety, 2019, 42 : 281 - 294
[2] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
Baraibar, Iosune
Melero, Ignacio
Ponz-Sarvise, Mariano
Castanon, Eduardo
DRUG SAFETY, 2019, 42 (02) : 281 - 294
[3] Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
Alessio Cortellini
Maria G. Vitale
Federica De Galitiis
Francesca R. Di Pietro
Rossana Berardi
Mariangela Torniai
Michele De Tursi
Antonino Grassadonia
Pietro Di Marino
Daniele Santini
Tea Zeppola
Cecilia Anesi
Alain Gelibter
Mario Alberto Occhipinti
Andrea Botticelli
Paolo Marchetti
Francesca Rastelli
Federica Pergolesi
Marianna Tudini
Rosa Rita Silva
Domenico Mallardo
Vito Vanella
Corrado Ficorella
Giampiero Porzio
Paolo A. Ascierto
Journal of Translational Medicine, 17
[4] Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
Cortellini, Alessio
Vitale, Maria G.
De Galitiis, Federica
Di Pietro, Francesca R.
Berardi, Rossana
Torniai, Mariangela
De Tursi, Michele
Grassadonia, Antonino
Di Marino, Pietro
Santini, Daniele
Zeppola, Tea
Anesi, Cecilia
Gelibter, Alain
Occhipinti, Mario Alberto
Botticelli, Andrea
Marchetti, Paolo
Rastelli, Francesca
Pergolesi, Federica
Tudini, Marianna
Silva, Rosa Rita
Mallardo, Domenico
Vanella, Vito
Ficorella, Corrado
Porzio, Giampiero
Ascierto, Paolo A.
JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (01)
[5] Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas
Ribatti, Domenico
Cazzato, Gerardo
Tamma, Roberto
Annese, Tiziana
Ingravallo, Giuseppe
Specchia, Giorgina
FRONTIERS IN ONCOLOGY, 2024, 14
[6] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Liu, Jinhua
Chen, Zichao
Li, Yaqun
Zhao, Wenjie
Wu, JiBiao
Zhang, Zhen
FRONTIERS IN PHARMACOLOGY, 2021, 12
[7] Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
Tang, Hui
Geng, Ruixuan
Xu, Xiuxiu
Wang, Yingyi
Zhou, Jiaxin
Zhang, Shulan
Zhao, Lin
Guan, Mei
Bai, Chunmei
FRONTIERS IN IMMUNOLOGY, 2022, 13
[8] Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer
Wan, Xiaoyan
Huang, Jiezheng
Huang, Liu
Wang, Yibin
Fu, Yiyuan
Jin, Xiaolong
Huang, Zheng
Xiong, Jian
DISCOVER ONCOLOGY, 2024, 15 (01)
[9] Effect of region on the Outcome of Patients Receiving PD-1/PD-L1 Inhibitors for Advanced Cancer
Wang, Ziheng
Zhang, Bo
Zhang, Chenlin
Ren, Shiqi
Wang, Wei
Wang, Yingjing
Jiang, Tao
Wei, Hualin
Li, Yang
Wu, Qiong
Chen, Jianfeng
INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 74
[10] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
Monneur, Audrey
Goncalves, Anthony
Bertucci, Francois
BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272

← 1 2 3 4 5 →